SecBot SecBot
SECBOTREPLAY Home › Report › ABT

ABT · Abbott reported Q2 2026 adjusted diluted EPS of $1.31, a 2.6% beat vs

ABBOTT LABORATORIES · 8-K filed Jul 16, 2026 at 07:36 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jul 16, 2026 at 07:36 ET

Abbott reported Q2 2026 adjusted diluted EPS of $1.31, a 2.6% beat vs. consensus of $1.28, on reported sales of $12.593B (vs. $12.52B consensus). Comparable sales grew 4.8% YoY. The company raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58, while reaffirming comparable sales growth of 6.5%-7.5%. GAAP EPS was $0.53, depressed by $1.362B in specified items including $385M in legal reserves and $658M in intangible amortization.

  • Adjusted diluted EPS of $1.31 beat consensus of $1.28 by 2.6%
  • Reported sales of $12.593B vs. consensus of $12.52B, up 13.0% reported / 4.8% comparable YoY
  • Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58
  • Full-year 2026 comparable sales growth guidance reaffirmed at 6.5%-7.5%

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access